PMID- 18037913
OWN - NLM
STAT- MEDLINE
DCOM- 20080520
LR  - 20211020
IS  - 0007-1188 (Print)
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
VI  - 153
IP  - 3
DP  - 2008 Feb
TI  - Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy 
      methamphetamine (MDMA) on body temperature in the mouse.
PG  - 591-7
AB  - BACKGROUND AND PURPOSE: We have investigated the ability of alpha(1)-adrenoceptor 
      antagonists to affect the hyperthermia produced by methylenedioxy methamphetamine 
      (MDMA) in conscious mice. EXPERIMENTAL APPROACH: Mice were implanted with 
      temperature probes under ether anaesthesia and allowed 2 weeks recovery. MDMA (20 
      mg kg(-1)) was administered subcutaneously 30 min after vehicle or test 
      antagonist or combination of antagonists and effects on body temperature 
      monitored. KEY RESULTS: Following vehicle, MDMA produced a hyperthermia, reaching 
      a maximum increase of 1.8 degrees C at 140 min. Prazosin (0.1 mg kg(-1)) revealed 
      an early significant hypothermia to MDMA of -1.94 degrees C. The 
      alpha(1A)-adrenoceptor antagonist RS 100329 (0.1 mg kg(-1)), or the 
      alpha(1D)-adrenoceptor antagonist BMY 7378 (0.5 mg kg(-1)) given alone, did not 
      reveal a hypothermia to MDMA, but the combination of the two antagonists revealed 
      a significant hypothermia to MDMA. The putative alpha(1B)-adrenoceptor antagonist 
      cyclazosin (1 mg kg(-1)) also revealed a significant hypothermia to MDMA, but 
      actions of cyclazosin at the other alpha(1)-adrenoceptor subtypes cannot be 
      excluded. CONCLUSIONS AND IMPLICATIONS: More than one subtype of 
      alpha(1)-adrenoceptor is involved in a component of the hyperthermic response to 
      MDMA in mouse, probably both alpha(1A)- and alpha(1D)-adrenoceptors, and removal 
      of this alpha(1)-adrenoceptor-mediated component reveals an initial hypothermia.
FAU - Bexis, S
AU  - Bexis S
AD  - Department of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
FAU - Docherty, J R
AU  - Docherty JR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071126
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Adra1a protein, mouse)
RN  - 0 (Adra1d protein, mouse)
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Piperazines)
RN  - 0 (Quinazolines)
RN  - 0 (Quinoxalines)
RN  - 0 (RS 100329)
RN  - 0 (Receptors, Adrenergic, alpha-1)
RN  - 139953-73-4 (cyclazosin)
RN  - KC07KV8T5O (BMY 7378)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - QR26YLT7LT (Thymine)
RN  - XM03YJ541D (Prazosin)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/*adverse effects/pharmacology
MH  - Adrenergic alpha-Antagonists/pharmacology
MH  - Animals
MH  - Body Temperature/*drug effects
MH  - Fever/chemically induced
MH  - Male
MH  - Mice
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects/pharmacology
MH  - Piperazines/pharmacology
MH  - Prazosin/pharmacology
MH  - Quinazolines/pharmacology
MH  - Quinoxalines/pharmacology
MH  - Receptors, Adrenergic, alpha-1/*drug effects/metabolism
MH  - Thymine/pharmacology
PMC - PMC2241778
EDAT- 2007/11/27 09:00
MHDA- 2008/05/21 09:00
PMCR- 2009/02/01
CRDT- 2007/11/27 09:00
PHST- 2007/11/27 09:00 [pubmed]
PHST- 2008/05/21 09:00 [medline]
PHST- 2007/11/27 09:00 [entrez]
PHST- 2009/02/01 00:00 [pmc-release]
AID - 0707590 [pii]
AID - 10.1038/sj.bjp.0707590 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2008 Feb;153(3):591-7. doi: 10.1038/sj.bjp.0707590. Epub 2007 Nov 
      26.